Please find enclosed herewith the Notice of the AGM for F.Y. 2025-26

Ganga Pharmaceuticals Limited CIN: L99999MH1989PLC053392 Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305 Phone No: 9834613142 | Website: www.ayurvedganga.com | Email: ayurvedganga@gmail.com. September 01, 2026 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001 Scrip Code: 539680 Sub: Notice convening the 37" Annual General Meeting (“AGM”) and Integrated Annual Report for Financial year 2025-26 Dear Sir/Madam, Please take note that: (a) Pursuant to the MCA Circulars and SEBI Circulars issued from time to time, the 37" Annual General Meeting (AGM) of the Company will be held Saturday, September 26, 2026 at 4:30 p.m. at the registered office of the Company at Gangatat, Dhanvantri Marg, Gopcharpada, Virar East, Palghar- 401305 (b)) The Company has fixed Friday, September 18, 2026, as the "Cut-off Date" for determining the eligibility of Members to vote by remote e-voting or e-voting at the Annual General Meeting, () The Company will be availing remote e-voting system of Central Depository Services Limited (CSDL) for casting vote for AGM. The remote e-voting period shall commence on Wednesday, September 23, 2026 (9:00 A.M.) and end on Friday, September 25, 2026 (5:00 P.M.). (d) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Register of Members and Share Transfer Books of the Company will remain closed for the urpose of Annual General Meeting, as detailed below; Symbol | Typeof | Book Closure Date Cut-Off Date Security 539680 | Equity Book Closure will start from Sunday, September 20, | Friday, Shares 2026, to Saturday, September 26, 2026 (both days | September 18, inclusive) for the purpose of Annual General Meeting | 2026 for financial year 2025-26 Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations ~and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report for the Financial Year 2025-2026 along with the Notice of the 37" Annual General Meeting (“AGM”) of the Company to be held on Saturday, September 26, 2026, at 04:30 P.M. (IST) at the registered office of the Company which is being sent through permissible modes to the Members of the Company. The Notice of the AGM and the Annual Report has also been uploaded on the website of the Company at www.ayurvedganga.com Kindly take the same in your records. Thanking You, Yours faithfully, For Ganga Pharmaceuticals Limited SHARMA biai™ BHARAT 5™® B8h arat Sh19a09r00m +a05' 30° Managing Director DIN: 00077026 Email Id.: bharat.sharma@gangapharma.in. Encl: As above GANGA PHARMACEUTICALS LIMITED 37" ANNUAL REPORT 2025-26 fifi GANGA 37th Annual Report 2025-2026 PUERMATEUNCALS (1D, GANGA PHARMACEUTICALS LIMITED Annual Report: 2025-26 CIN : L99999MH1989PLC053392 Registered office : Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar- 401305 Works and Factory : Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar- 401305 Board of Directors : Mr. Sanjay Vyankatesh Kulkarni (Non-Executive Chairman) Mr. Bharat Brijmohan Sharma (Managing Director & CEO) Mrs. Srijna Bharat Sharma (Whole time Director) Mr. Munna Baijnath Chaurasia (Independent Director) Mr. Aman Mukesh Chaudhari (Independent Director) Key Managerial : Mr. Anagh Sharma (Chief Financial Officer) Personnel Mrs. Priti Bhaiya (Company Secretary & Compliance Officer) Bankers 1 Union Bank of India StatutoryAuditor : Banka & Banka Chartered Accountants. Shah Trade Centre 3rd floor, above State bank of India, Rani Sati Marg, Malad East, Mumbai-400 097 Share Registrar & : KFin Technologies Limited Transfer Agent Selenium, Tower - B, Plot No. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana - 500032. Website © www.ayurvedganga.com Contents Page. No. Notice 02 Board’s Report 11 Annexure to the Board's Report 22 Management Discussion & Analysis Report 27 Auditor’s Report 29 Balance Sheet 38 Statement of Profit & Loss Account 39 Cash Flow Statement 40 Notes to Financial Statements 42 CEO& CFO Certificate 56 Attendance Slip and Proxy Form 57 Route Map 59 g 11 GANGA 37th Annual Report 2025-2026 "PHERMACEUTICALS (7P, NOTICE OF ANNUAL GENERAL MEETING NOTICE is hereby given that the 37" (Thirty Seventh) Annual General Meeting of the Members of Ganga Pharmaceuticals Limited (“the Company”) will be held on Saturday, September 26, 2026 at 4.30 p.m. at the registered office of the Company at Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palgh—a 40r1 305 to transact the following businesses: Ordinary Business: 1. Adoption of the Audited Financial Statements of the Company To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026 including the Audited Balance Sheet as at March 31, 2026 and the Statement of Profit and Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon; and 2. Toappointa Director in place of Mr. Sanjay Kulkarni (DIN: 00065190), who retires by rotation and being eligible, has offered himself for re-appointment SPECIAL BUSINESS: 3. Re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director & Chief Executive Officer (CEO) of the Company. To consider and if thought fit, to pass the following resolution as an Ordinary Resolution; “RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 (‘the Act’) and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), the Articles of Association of the Company, and subject to such other approvals, permissions, and sanctions as may be required, and based on the recommendations of the Nomination and Remuneration Committee, Audit Committee, and the Board of Directors, the consent of the Members of the Company be and is hereby accorded for the re-appointment of Mr. Bharat Brijmohan Sharma (DIN: 00077026) as the Managing Director & Chief Executive Officer (CEO) of the Company, for a period of three (3) years with effect from April 01, 2026, to March 31, 2029, upon the terms and conditions including remuneration, allowances, and perquisites as set out in the Explanatory Statement annexed hereto, with further liberty to the Board of Directors (hereinafter referred to as ‘the Board’, which term shall include any Committee constituted by the Board) to alter, vary, or revise the terms and conditions of the said re-appointment and/or remuneration from time to time, provided it does not exceed the limits specified under Section 197 and Schedule V to the Act.; RESOLVED FURTHER THAT pursuant to Section 203 of the Act, Mr. Bharat Brijmohan Sharma shall continue to function as a Key Managerial Personnel (KMP) of the Company and his office as Managing Director & CEO shall not be liable to retire by rotation during his tenure; RESOLVED FURTHER THAT where in any financial year during the currency of the tenure of Mr. Bharat Brijmohan Sharma, the Company has no profits or its profits are inadequate, the Company shall pay to Mr. Bharat Brijmohan Sharma the remuneration, perquisites, and allowances as specified in the Explanatory Statement as the Minimum Remuneration, subject to compliance with the applicable provisions of Schedule V of the Act, or such other limits as may be prescribed by the Central Government or via statutory modifications from time to time; RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds and things and execute all such documents, instruments and writings as may be required and to delegate all or any of its powers herein confe [Showing first 8,000 characters — download PDF for full document]